Extracorporeal photopheresis (ECP) has become a recognised treatment for steroid-refractory chronic GVHD (cGVHD), but the optimal frequency and duration of treatment are yet to be established. We report on 82 consecutive patients with mucocutaneous cGVHD who received a bimonthly regimen of ECP treatment for two consecutive days, which could be subsequently tapered to a monthly regimen depending on response. Patients were steroid-refractory, steroid-dependent or steroid-intolerant, and 29 (35%) had multiorgan involvement. The median duration of treatment was 330 days (42-987). The median number of ECP cycles was 15 (1.5-32). Response was assessed by clinical assessment and reduction in immunosuppression after 6 months. 69/82 (84%) had completed 6 months of ECP and 65/69 (94%) had X50% improvement in symptoms and signs of cGVHD. A total of 77% of patients who completed 6 months of ECP had a reduction in immunosuppression dose and 80% had decreased their steroid dose (27.5% stopped, 30% had X75% reduction, 17.5% had X50% reduction and 25% had o50% reduction). OS at 3 years from the start of ECP was 69%. This study reports the largest series of patients receiving bimonthly ECP treatment for cGVHD, and confirms that ECP allows successful reduction of immunosuppression.
Introduction
Chronic GVHD (cGVHD) is a common complication following Allo-SCT, and is the leading cause of late nonrelapse mortality. 1 Treatment of cGVHD is challenging. Immunosuppressive agents such as steroids and calcineurin inhibitors provide the mainstay of treatment but are associated with an increased incidence of infection, 2, 3 and have a major impact on morbidity and mortality in cGVHD. Patients who are refractory to steroids are particularly difficult to manage. A number of second-line therapies exist, 4 including cytotoxics, MoAbs and mycophenolate mofetil, but have limited efficacy at B30%. 5 Furthermore, patients can require immunosuppressive medication for prolonged periods with Stewart et al. 6 reporting a median duration of 23 months of treatment. Long-lasting treatment is associated with a significant decrease in health-related quality of life. 7 Bhatia et al. 8 reported the relative risk of death to be 2.7 in patients with cGVHD. Extracorporeal photopheresis (ECP) is a cell-based immune-modulatory therapy, which offers a different therapeutic approach for cGVHD. The mode of action of ECP in cGVHD remains poorly understood and may be multifactorial in nature. 9 The main proposed mechanism of action is that ECP induces apoptosis of activated T cells. The reinfusion of these cells is thought to cause immune homoeostasis through modulation of cytokine production. 10, 11 Owsianowski et al. 12 first reported the use of ECP in cGVHD in 1994 in one patient who had an improvement in lichenified skin changes, joint contractures and sicca syndrome. Promising multiorgan responses have been reported in patients with cGVHD in several non-randomised, nonblinded studies. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Flowers et al. 24 have recently published the first multicentre, randomised controlled, prospective phase II trial of ECP in the treatment of patients with cGVHD. The study used percentage improvement in total skin scores after 12 weeks of ECP treatment as the primary endpoint. The percentage reduction in total skin score from baseline was greater in the ECP arm compared with the non-ECP arm, but this did not achieve statistical significance (P ¼ 0.48). The proportion of patients who had at least a 50% reduction in steroid dose and at least a 25% decrease in total skin score was 8.3% in the ECP arm at week 12 and 0% in the control arm (P ¼ 0.04). Current guidelines suggest that ECP is a useful second-line treatment option in cGVHD, 4 and that it is particularly efficacious in patients with skin, mucosal membranes (eye/mouth) or liver involvement. 25 There is currently no consensus on the optimal frequency and duration of treatment.
In the current study, we report the efficacy of ECP in a large cohort of patients with cGVHD who all received bimonthly ECP. A bimonthly schedule was used as many patients travelled long distances to the treatment centre. As previous studies, including the randomised controlled trial, have demonstrated that steroid reduction was possible on ECP, the current study used both change in immunosuppression dose at 6 months and clinical assessment as response criteria.
Patients and methods

Patient population
From December 2005 to February 2010, a total of 82 consecutive patients commenced ECP treatment for mucocutaneous cGVHD. Patients were referred from transplant centres in southern England to St John's Institute of Dermatology, St Thomas' Hospital in London, UK, at the discretion of the transplant physician. All patients were steroid-refractory, steroid-dependent or intolerant of steroids. All patients gave informed consent to undergo treatment. Data were collected from the unit's ECP database.
Chronic GVHD
Patients with oral or skin involvement with cGVHD were identified for this study. Skin manifestations were diagnosed on clinical grounds, if typical sclerodermoid changes were present. A biopsy was performed to confirm the diagnosis of lichenoid skin GVHD. Involvement of the oral mucosa was diagnosed clinically by the appearance of lichenoid changes, erythema, mucoceles or ulcers. The involvement of other organs was also documented. Ocular and joint involvement were diagnosed on the basis of clinical features. Liver GVHD was diagnosed based on clinical grounds using liver function test abnormalities and biopsy results where feasible. Gut GVHD was diagnosed according to clinical features and biopsy results.
Patients received treatment for cGVHD according to the protocol of the referring transplant centres. Unless otherwise indicated, corticosteroids were tapered first followed by alternative immunosuppressive drugs. The schedule for tapering steroids was at the discretion of the transplant physician.
Response criteria
Clinical assessment of the symptoms and signs of cGVHD in all patients was conducted by a single unblinded investigator (JJS). Clinical assessment included the documentation of skin and oral involvement as detailed in the National Institutes of Health (NIH) consensus development project on criteria for clinical trials. 26 Response was assessed at the time of clinical review and was prospectively entered into the unit's ECP database. A complete clinical response was defined as a complete resolution of all symptoms and signs of GVHD, and a partial clinical response was defined as a 50% improvement in skin or oral disease when compared with baseline. Improvement was measured in terms of percentage of body surface area involved with cutaneous cGVHD and the percentage of oral mucosa involved with erythema or lichenoid change, and the presence of ulceration or mucoceles.
In addition to organ response, reduction of immunosuppression at 6 months was used as a global measure of response to ECP as many patients had multiorgan involvement, and response in organs varied. In patients who were receiving corticosteroids, the dose that patients were receiving at 6 months was compared with the dose when they started ECP treatment. In patients who were not receiving corticosteroids, the dose of other immunosuppressive drugs at 6 months was compared with the dose at the start of treatment.
Extracorporeal photopheresis ECP treatment was administered on two consecutive days every 2 weeks until a partial clinical response (450% improvement) was reported, and was then reduced to monthly treatments. A cycle was defined as two ECP treatments. Patients were assessed at three monthly intervals. Venous access was obtained peripherally or by using an indwelling apheresis catheter. The duration of treatment was 3-4 h.
ECP was performed using the UVAR XTS photopheresis system (Therakos, Ascot, UK). Six cycles were performed for each treatment using a 125 mL bowl. After collection of the buffy coat, liquid methoxsalen (UVADEX) was injected into the recirculation bag of the ECP circuit before the photoactivation process. The dose of UVADEX (Therakos, Ascot, UK) was calculated based on the volume of buffy coat collected. Photoactivation commenced during the first cycle of buffy coat collection. Heparinised saline was mixed with the buffy coat, and the mixture was exposed to the UVA light in the photoactivation chamber.
Blood parameters
Full blood count, urea and electrolytes, and liver function tests were measured at the start of treatment and at each cycle of ECP treatment. Lactate dehydrogenase level and lymphocyte subsets were also measured every 3 months.
Statistical analysis
Descriptive data were summarised using median values, ranges and percentages. OS since the start of ECP treatment was analysed using the Kaplan-Meier method. Analysis was undertaken using SPSS version 18.0 (SPSS, Chicago, IL, USA).
Results
Demographics
Patient characteristics are summarised in Table 1 . The median time from transplant to commencing ECP was 2.4 years (6 months-10 years). Using the NIH scoring system for cGVHD, 75/82 (91%) of patients had severe disease and 7/82 (9%) had moderate disease. 27 A total of 33 patients had de novo cGVHD and 24 had progressive disease. A total of 18 patients had developed GVHD following donor lymphocyte infusion. Details of disease onset were not known in seven patients. A total of 75 patients (91%) had cutaneous skin disease, 40 had sclerodermoid disease and 34 had lichenoid disease. One patient had features of both sclerodermoid and lichenoid disease. A total of 39 (48%) patients had oral disease. Other organs involved included liver (11), eyes (18) , gut (3), lung (2) and joint (1) .
At the start of ECP, 70 patients were on immunosuppressive drugs. In all, 12 patients were not receiving any GVHD treatment at time of referral, but had a previous history of steroid intolerance or steroid-refractory disease. A detailed description of GVHD treatment at start of ECP is given in Table 2 . The median dose of prednisolone at the start of treatment was 25 mg (5-135 mg). The median dose of CsA was 75 mg twice daily (20-200 mg twice daily). The median dose of mycophenolate mofetil was 2 g/day (1-3.5 g).
The median platelet count at the start of treatment was 253 Â 10 9 /L (25-790 Â 10 9 /L). Nine patients had a platelet count of o100 at the start of ECP, a feature associated with poor prognosis of GVHD. 28 The median lactate dehydrogenase level at the start of treatment was 478 units/L (240-1867 IU/L). Nine patients had a lactate dehydrogenase level 41000 at the start of treatment (normal range: 240-480 IU/L).
Duration of ECP treatment
A total of 52 patients were no longer receiving ECP at the time of analysis. A total of 30 patients were receiving ongoing treatment but had received at least 6 months of ECP. The median duration of ECP in those that had completed ECP was 330 days (42-987). The median number of ECP cycles received was 15 (1.5-32 cycles). In all, 50 patients had reduced the frequency of ECP to monthly. The median time to reduction of treatment was 207 days (74-638 days).
Response
Clinical assessment. 69/82 patients were evaluable for response following 6 months ECP. 6/82 died and 7/82 had completed o6 months of treatment. Patients were reassessed in terms of skin scores, oral scores and functional status. Assuming that the patients who died or did not (6), completed o6 months of treatment (7) or dosage data were missing (4) . Assuming that the patients who died or did not complete 6 months of ECP did not respond to treatment, 41/66 (62%) had a reduction in immunosuppression. 41/53 (77%) of patients who completed 6 months of ECP had a reduction in immunosuppressive dose.
Reduction in steroid dose. 63/70 patients were receiving steroids at the start of ECP treatment. 50/63 were evaluable for assessment at 6 months. 40/50 (80%) had a dose reduction (11 stopped completely, 12X75% reduction, 7X50% reduction and 10o50% reduction). Five patients' doses were stable and five had increased. The median dose was 10 mg (3-50 mg). Figure 1 is a flow chart showing change in dose in patients who were on steroids at the start of ECP treatment. 7/70 patients were not receiving steroids at the start of ECP but were receiving an alternative immunosuppressive medication. 3/7 were evaluable for assessment at 6 months. One required steroids, one had a dose reduction and one remained on a stable dose.
Reduction in CsA dose. In the 39 patients who were receiving CsA at the start of treatment, data were available in 33 after 6 months of ECP treatment. Six patients had stopped CsA and, in the remainder, the median dose had reduced to 117.5 mg/day (37.5-400 mg/day).
Outcome in patients not receiving immunosuppression. A total of 12 patients were not on immunosuppression at the start of ECP. Three had recommenced steroids during treatment, one had recommenced CsA and mycophenolate mofetil, and eight remained on no systemic immunosuppression after 6 months of treatment.
Outcome in patients with platelet count o100 Â 10 9 /L. Nine patients had a platelet count of o100 Â 10 9 /L. Two patients died, two completed o6 months of treatment and four had a X50% reduction in immunosuppression. Dosage data were missing for the remaining patient.
Survival. All patients were considered evaluable for survival, including those who had completed o6 months of treatment. OS at 3 years from start of ECP was 69% (Figure 2 ). A total of 19 patients died. Investigators recorded the cause of death as: GVHD alone in four patients, infection in five patients, and infection and GVHD in seven patients. Two patients died of relapsed disease, and the cause of death in the remaining patient is unknown.
Toxicity. Four patients developed indwelling line infections during the course of ECP treatment. Three patients had an increase in red cell transfusion requirements, but there were no reports of iron deficiency anaemia in longterm ECP patients. There were no other complications of ECP treatment reported to the unit.
Discussion
This study includes the largest series of patients treated for steroid-refractory mucocutaneous cGVHD with ECP to date. This report is also the first to use a standardised bimonthly regimen of ECP, which may be more practical for patients that have to travel to receive the ECP treatment. Response was assessed using both the clinical assessment and the reduction in immunosuppressive medications.
Response criteria have varied in the existing literature. The majority of studies use clinical assessment as the primary assessment of response. 14, 16, 18, 23 In the only randomised controlled trial to date, reduction in steroid dose was included as a secondary objective. 24 In the current study, reduction of immunosuppression at 6 months was used as a global measure of response to ECP in addition to clinical assessment. The current study reports that 77% of patients who completed 6 months of ECP treatment had a reduction in immunosuppression, which is comparable to the clinical response rates reported by other investigators. It may be that this figure represents a good risk group as all patients tolerated 6 months of ECP treatment, and it may be that some of the patients who were not evaluable were too unwell to attend for ECP owing to progression of cGVHD. Despite this limitation, the response rate remains encouraging as patients were steroid-dependent, steroidrefractory or steroid-intolerant, and the majority were receiving two or more immunosuppressive agents.
There is also variation in the treatment schedules and duration of ECP in the literature. Some include a variety of treatment schedules, 14, 15 while others reduce the frequency depending on response. 16, 23 Couriel et al. 23 report a very intensive initial regimen of 2-4 treatments per week, which was reduced according to response and a median of 32 ECP procedures. Jagasia et al. 18 report a median of 12 ECP treatments and commenced ECP on a weekly basis. One of the particular advantages of this study is that all patients received the same treatment schedule of two consecutive ECP treatments every fortnight. This report suggests that this regimen is feasible and effective in the management of cGVHD. This two-weekly schedule may be more feasible for centres where patients have to travel a long distance for treatment. The median number of ECP cycles was 15 (30 treatments), and the median duration of treatment was 330 days. This information may be helpful when counselling patients about the treatment, and for providing information to commissioners responsible for funding the service, particularly in centres where patients will receive treatment at two-weekly intervals.
There are several limitations to the current study. Assessment was made by a single unblinded observer, which may have led to bias in the reporting of clinical response rates. The use of the NIH assessment criteria may have helped to minimise investigator bias. In addition, patients were receiving a variety of immunosuppression regimens for cGVHD when they started ECP treatment. This reflects the large number of referral centres and the general lack of standardisation of cGVHD treatment. In view of this wide variation in treatment, this study includes significant detail about individual immunosuppressive regimens, and uses both clinical assessment and reduction of immunosuppression to assess response.
Survival has been variable among the reports in the literature, and severe skin involvement of 450% has been identified as a poor prognostic indicator for survival. 29 In one of the largest series to date, Couriel et al. 23 report a 5-year survival rate of 19% in steroid-refractory cGVHD following initiation of ECP. Jagasia et al. 18 reported a higher survival of 52% at 3 years from start of ECP in patients with classic cGVHD. Our study included patients with steroid-refractory mucocutaneous cGVHD, and OS at 3 years was 69%. This survival rate is slightly higher than that previously demonstrated, and may reflect the fact that St Thomas' Hospital is the regional referral centre for a large geographical area. Patients often have to travel a long way for treatment and may therefore have a generally higher performance status than those treated in their own centres. There does not seem, however, to be a significant difference in risk in terms of use of immunosuppressive drugs, as 77% were receiving corticosteroid therapy at time of initiation of ECP, which is similar to previous reports. 23 This study reports the largest series of patients receiving bimonthly ECP treatment for cGVHD. We confirm that this ECP schedule is effective in steroid-refractory cGVHD, with 77% of patients who completed 6 months of ECP 
